Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Provalis' POC (point-of-care) diabetes monitor:

This article was originally published in Clinica

Executive Summary

UK company Provalis has received US FDA 510(k) clearance to market its point-of-care diabetes monitor. Glycosal, a simple four-minute test for glycated haemoglobin, can be used to help monitor the severity of diabetes and the effectiveness of long-term therapy. The device measures a diabetic's average level of glucose over the last three months by measuring a specific fraction of the patient's haemoglobin called HbA1c. Deeside-based Provalis said that the product is already available in over 20 markets in Europe, South America and the Far East. It will now apply for a CLIA waiver to bring the testing device to a larger market in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel